Kangmei Pharmaceutical announced that the "other risk warning" situation triggered by the negative opinion issued on the internal control audit report for the year 2020 has been eliminated, and the Bohai Trust case has been judged effective and entered the execution procedure. The company's profitability continues to increase. In 2023, the company's operating income was 4874.02 million yuan, a year-on-year increase of 16.60%. The net income attributable to shareholders of the listed company was 102.52 million yuan, realizing a turnaround from losses to profits. The company will apply to the Shanghai Stock Exchange for the revocation of the "other risk warning", and the final result is subject to the review opinion.
ST康美：申请撤销其他风险警示
Kangmei Pharmaceutical: Apply for the revocation of other risk warnings.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.